Policosanol Cholesterol Randomized Trial: What the Evidence Says

Quick Answer

Policosanol Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Hypertension is the most significant controllable risk factor for cardiovascular diseases, accounting for about 57% of all cardiovascular-related deaths. [Revueltas Aguero Moura (2025); evidence level 2]
• In addition, hypertension has been strongly associated with an increased risk of coronary heart disease, stroke, chronic kidney disease, and all-cause mortality. [Revueltas Aguero Moura (2025); evidence level 2]
• Hypertension is the most frequent modifiable cardiovascular risk factor, with more than 1 billion individuals living with high blood pressure worldwide. [Revueltas Moura (2025); evidence level 2]
• Evidence has proven the impact of lowering blood pressure for improving cardiovascular outcomes and all-cause mortality, making clear the relevance of promoting knowledge, prevention, and treatment of high blood pressure levels. [Revueltas Moura (2025); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For policosanol cholesterol randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Revueltas Aguero Moura (2025). Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double‐Blind, Multicenter Study. DOI: 10.1111/jch.70126. PMCID: PMC12487964. PMID: 41032504. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12487964/
• Revueltas Moura (2025). Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double‐Blind, Multicentre Study. DOI: 10.1111/jch.14948. PMCID: PMC11973123. PMID: 40189869. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC11973123/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.